The impact of trastuzumab on radiation-induced pulmonary fibrosis: Results of an experimental study

Medical Oncology

Volumn 27, Issue 4, 2010, Pages 1415-1419

  Bese, N S ^a   Umay, C ^a   Serdengecti, S ^a   Kepil, N ^a   Sut, N ^b   Altug, T ^a   Ober, A ^a  

^a ISTANBUL UNIVERSITY   (Turkey)

^b TRAKYA UNIVERSITY   (Turkey)

Author keywords

Late toxicity; Radiation therapy; Trastuzumab

Indexed keywords

TRASTUZUMAB;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER RADIOTHERAPY; CONTROLLED STUDY; DRUG SAFETY; EXPERIMENTAL STUDY; FEMALE; HISTOPATHOLOGY; LUNG FIBROSIS; NONHUMAN; PRIORITY JOURNAL; RADIATION DEPTH DOSE; RADIATION DOSE; RADIATION INJURY; RAT; SCORING SYSTEM;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; FEMALE; PROGNOSIS; PULMONARY FIBROSIS; RADIATION INJURIES, EXPERIMENTAL; RATS; RATS, WISTAR;

EID: 79951770565     PISSN: 13570560     EISSN: None     Source Type: Journal    
DOI: 10.1007/s12032-009-9395-5     Document Type: Article

References (24)

1. Slamon DJ, et al. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science. 1987;235:177-82. (Pubitemid 17231334)
2. Belkacémi Y, et al. Concurrent trastuzumab with adjuvant radiotherapy in HER2-positive breast cancer patients: acute toxicity analyses from the French multicentric study. Ann Oncol. 2008;19:1110-6. (Pubitemid 351796336)
3. Romond EH, et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med. 2005;353:1673-84. (Pubitemid 41464706)
4. Piccart-Gebhart MJ, et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med. 2005;353:1659-72. (Pubitemid 41464705)
5. Smith I, et al. 2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial. Lancet. 2007;369:29-36. (Pubitemid 46039831)
6. Joensuu H, et al. Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer. N Engl J Med. 2006;23(354):809-20. (Pubitemid 43290919)
7. Whelan T, Darby S, Taylor S, McGale P, Ewertz M. 2006 update of the early breast cancer trialists' collaborative group overview of radiation therapy for early breast cancer. ASCO Educational Booklet. 2007;3:6.
8. Fisher B, et al. Twenty-year follow-up of a randomized trial comparing total mastectomy, lumpectomy, and lumpectomy plus irradiation for the treatment of invasive breast cancer. N Engl J Med. 2002;347:1233-41. (Pubitemid 35176242)
9. Pietras RJ, et al. Monoclonal antibody to HER-2/neureceptor modulates repair of radiation-induced DNA damage and enhances radiosensitivity of human breast cancer cells overexpressing this oncogene. Cancer Res. 1999;59:1347-55. (Pubitemid 29136268)
10. Raben S, et al. Comparison of acute breast and chest wall toxicity in women treated with external beam radiation with and without concurrent herceptin in a community cancer center. Int J Radiat Oncol Biol Phys. 2006;66(Suppl. 1): S541-2.
11. Bellon JR, Gover MT, Burstein HJ, Harris JR, Harris LN. Concurrent Trastuzumab and radiation therapy in the adjuvant treatment of breast cancer. Int J Radiat Oncol Biol Phys. 2005;63(Suppl. 1): S55-6.
12. Halyard MY, et al. Radiotherapy and adjuvant trastuzumab in operable breast cancer: tolerability and adverse event data from the NCCTG Phase III Trial N9831. J Clin Oncol. 2009;27:2638-44.
13. Horton JK et al. Radiosensitization of chemotherapy-refractory, locally advanced or locally recurrent breast cancer with Trastuzumab: a phase II Trial. Int J Radiat Oncol Biol Phys. 2009 Jun. 26. [Epub ahead of print].
14. Bese NS, et al. The effects of tamoxifen on radiation-induced pulmonary fibrosis in Wistar albino rats: results of an experimental study. Breast. 2006;15:456-60.
15. Pegram M, Ngo D. Application and potential limitations if animal models utilized in the development of trastuzumab: a case study advanced drug delivery reviews. Adv Drug Deliv Rev. 2006;58:732-4.
16. Ward HE, Kemsley L, Davies L, Holecek M, Berend N. The pulmonary response to sublethal thoracic irradiation in the rat. Radiat Res. 1993;136:15-21. (Pubitemid 23342594)
17. Ashcroft T, Simpson JM. Timbrell V: simple method of estimating severity of pulmonary fibrosis on a numerical scale. J Clin Pathol. 1988;41:467-70. (Pubitemid 18098428)
18. Daniel WW. Biostatistics: a foundation for analysis in the health sciences. 6th ed. New York: Wiley; 1995. p. 273-312.
19. Sawyer DB, Zuppinger C, Miller TA, Eppenberger HM, Suter TM. Modulation of anthracycline-induced myofibrillar disarray in rat ventricular myocytes by neuregulin-1beta and anti-erbB2: potential mechanism for trastuzumab-induced cardiotoxicity. Circulation. 2002;105:1551-4. (Pubitemid 34297631)
20. Slamon DJ, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med. 2001;344:783-92. (Pubitemid 32222155)
21. Suter TM, et al. Trastuzumab-associated cardiac adverse effects in the herceptin adjuvant trial. J Clin Oncol. 2007;25:3859-65. (Pubitemid 47477261)
22. Bird BR, Swain SM. Cardiac toxicity in breast cancer survivors: review of potential cardiac problems. Clin Cancer Res. 2008;14:14-24. (Pubitemid 351377973)
23. Shaffer R, Tyldesley S, Rolles M, Chia S, Mohamed I. Acute cardiotoxicity with concurrent trastuzumab and radiotherapy including internal mammary chain nodes: a retrospective singleinstitution study. Radiother Oncol. 2009;90:122-6.
24. Stone HB, et al. Effects of radiation on normal tissue: consequences and mechanisms. Lancet Oncol. 2003;4:529-36. (Pubitemid 38351709)